Clinical development of 17-allylamino, 17-demethoxygeldanamycin

Current Cancer Drug Targets

Volumn 3, Issue 5, 2003, Pages 377-383

  Sausville, Edward A ^a   Tomaszewski, Joseph E ^a   Ivy, Percy ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; 17 AMINO 17 DEMETHOXYGELDANAMYCIN; ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; GELDANAMYCIN; HEAT SHOCK PROTEIN 90 INHIBITOR; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ALOPECIA; ANEMIA; ANOREXIA; BLOOD TOXICITY; CANCER INVASION; CARDIOTOXICITY; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL STUDY; CLINICAL TRIAL; DEHYDRATION; DIARRHEA; DOSE CALCULATION; DRUG DOSE REGIMEN; DRUG SAFETY; FATIGUE; FEVER; GASTROINTESTINAL SYMPTOM; HEART TAMPONADE; HUMAN; LIVER TOXICITY; METASTASIS; MYALGIA; NAUSEA; NEPHROTOXICITY; NONHUMAN; ONCOGENE; PROTEIN FOLDING; REVIEW; SIDE EFFECT; SOLID TUMOR; THROMBOCYTOPENIA; VOMITING;

ANIMALS; BENZOQUINONES; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; RIFABUTIN;

EID: 0141596326     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568009033481831     Document Type: Review

References (24)

1. Miller, P.; DiOrio, C.; Moyer, M.; Schnur, R. C.; Bruskin, A.; Cullen, W.; Moyer, J. D. Depletion of the erbB-2 Gene Product p185 by Benzoquinoid Ansamycins. Cancer Res. 1994, 54, 2724-2730.
2. Schulte, T. W.; Neckers, L. M. The Benzoquinone Ansamycin 17-Allylamino-17-demethoxygeldanamycin Binds to HSP90 and Shares Important Biologic Activities with Geldanamycin. Cancer Chemother. Pharmacol. 1998, 42, 273-279.
3. Supko, J. G.; Hickman, R. L.; Grever, M. R.; Malspeis, L. Preclinical Pharmacologic Evaluation of Geldanamycin as an Antitumor Agent. Cancer Chemother. Pharmacol. 1995, 36, 305-315.
4. Gelmon, K. A.; Eisenhauer, E. A.; Harris, A. L.; Ratain, M. J.; Workman, P. Anticancer Agents Targeting Signaling Molecules and Cancer Cell Environment: Challenges for Drug Development. J. Natl. Cancer Inst. 1999, 91, 1281-1287.
5. Kelland, L. R.; Sharp, S. Y.; Rogers, P. M., Myers T. G., Workman, P. DT-Diaphorase Expression and Tumor Cell Sensitivity to 17-Allylamino, 17-demethoxygeldanamycin, an Inhibitor of Heat Shock Protein 90. J. Natl. Cancer Inst. 1999, 91, 1940-1949.
6. Simon, R.; Freidlin, B.; Rubinstein, L.; Arbuck, S. G.; Collins, J.; Christian, M. C. Accelerated Titration Designs for Phase I Clinical Trials in Oncology. J. Natl. Cancer Inst. 1997, 89, 1138-1147.
7. Gerber, J. Drug Interaction Issues in Multidrug Therapy of HIV infection. In The PRN Notebook; Braun, J.; Flexner, C.; Starrett, B., Eds., 1999, pp. 16-20.
8. Goshman, L.; Fish, J.; Roller, K. Clinically Significant Cytochrome P450 Drug Interactions. In Journal of the Pharmacy Society of Wisconsin; Vermeulen, L., Ed. 1999, May/June. pp 23-38.
9. Egorin, M. J.; Rosen, D. M.; Wolff, J. H.; Callery, P. S.; Musser, S. M. ; Eiseman, J.L. Metabolism of 17-(Allylamino)-17-demethoxygeldanamycin (NSC 330507) by Murine and Human Hepatic Preparations. Cancer Res. 1998, 58, 2385-239.
10. Munster, P. N.; Srethapakdi, M.; Moasser, M. M.; Rosen N. Inhibition of Heat Shock Protein 90 Function by Ansamycins Causes the Morphological and Functional Differentiation of Breast Cancer Cells. Cancer Res. 2001, 61, 2945-2952.
11. Basso, A. D.; Solit, D. B.; Munster, P. N.; Rosen N. Ansamycin Antibiotics Inhibit Akt Activation and Cyclin D Expression in Breast Cancer Cells that Overexpress HER2. Oncogene. 2002, 21, 1159-1166.
12. Bagatell, R.; Khan, O.; Paine-Murrieta, G.; Taylor, C. W.; Akinaga, S.; Whitesell, L. Destabilization of Steroid Receptors by Heat Shock Protein 90-Binding Drugs: a Ligand-independent Approach to Hormonal Therapy of Breast Cancer. Clin. Cancer Res. 2001, 7, 2076-2084.
13. Solit, D. B; Zheng, F. F.; Drobnjak, M.; Munster, P. N.; Higgins, B.; Verbel, D.; Heller, G.; Tong, W.; Cordon-Cardo, C.; Agus, D.B.; Scher, H. I.; Rosen, N. 17-Allylamino-17-demethoxygeldanamycin Induces the Degradation of Androgen Receptor and HER-2/neu and Inhibits the Growth of Prostate Cancer Xenografts. Clin. Cancer Res. 2002, 8, 986-993.
14. Nguyen, D. M.; Desai, S.; Chen, A.; Weiser, T. S.; Schrump, D. S.; Modulation of Metastasis Phenotypes of Non-small Cell Lung Cancer Cells by 17-Allylamino 17-demethoxy geldanamycin. Ann. Thorac. Surg. 2000, 70, 1853-1860.
15. Nimmanapalli, R.; O'Bryan, E.; Bhalla, K. Geldanamycin and its Analogue 17-Allylamino-17-demethoxygeldanamycin Lowers Bcr-abl Levels and Induces Apoptosis and Differentiation of Bcr-abl-positive Human Leukemic Blasts. Cancer Res. 2001, 61, 1799-1804.
16. Bonvini, P.; Gastaldi, T.; Falini, B.; Rosolen, A. Nucleophosmin-anaplastic Lymphoma Kinase (NPM-ALK), a Novel Hsp90-Client Tyrosine Kinase: Down-Regulation of NPM-ALK Expression and Tyrosine Phosphorylation in ALK+ CD30+ Lymphoma Cells by the Hsp90 Antagonist 17-Allylamino, 17-demethoxygeldanamycin. Cancer Res. 2002, 62, 1559-1566.
17. Munster, P. N.; Basso, A.; Solit, D.; Norton, L.; Rosen, N. Modulation of Hsp90 Function by Ansamycins Sensitizes Breast Cancer Cells to Chemotherapy-induced Apoptosis in an RB- and Schedule-dependent Manner. Clin. Cancer Res. 2001, 7, 2228-2236.
18. Nguyen, D. M.; Lorang, D.; Chen, G. A.; Stewart, J. H. 4th; Tabibi, E.; Schrump, D. S.; Enhancement of Paclitaxel-mediated Cytotoxicity in Lung Cancer Cells by 17-Allylamino geldanamycin: In vitro and In vivo Analysis. Ann. Thorac. Surg. 2001, 72, 371-379.
19. Nguyen, D. M.; Chen, A.; Mixon, A.; Schrump, D. S. Sequence-dependent Enhancement of Paclitaxel Toxicity in Non-small Cell Lung Cancer by 17-Allylamino 17-demethoxygeldanamycin. J. Thorac. Cardiovasc. Surg. 1999, 118, 908-915.
20. Schulte, T. W.; Blagosklonny, M. V.; Romanova, L.; Mushinski, J. F.; Monia, B. P.; Johnston, J. F.; Nguyen, P.; Trepel, J.; Neckers, L. M. Destabilization of Raf-1 by Geldanamycin Leads to Disruption of the Raf-1-MEK-Mitogen-Activated Protein Kinase Signaling Pathway Mol. Cell Biol. 1996, 16, 5839-5845.
21. Munster, P. N.; Marchion, D. C.; Basso, A. D.; Rosen, N. Degradation of HER2 by Ansamycins Induces Growth Arrest and Apoptosis in Cells with HER2 Overexpression via a HER3, Phosphatidylinositol 3′kinase-AKT-dependent Pathway. Cancer Res. 2002, 62, 3132-3137.
22. Srethapakdi, M.; Liu, F.; Travorath, R.; Rosen, N. Inibition of Hsp90 Function by Ansamycins Causes Retinoblastoma Gene Product-dependent G1 Arrest. Cancer Res. 2000, 60, 3940-3946.
23. Webb, C. P.; Hose, C. D.; Koochepour, S.; Jeffers, M.; Oskarsson, M.; Sausville, E. A.; Monks, A.; Vande Woude, G. F. The Geldanamycins are Potent Inhibitors of the Hepatocyte Growth Factor/scatter factor-met-urokinase Plasminogen Activator-plasmin Proteolytic Network. Cancer Res. 2000, 60, 342-349.
24. Basso, A. D.; Solit, D. B.; Chiosis, G.; Giri, B.; Tsichlis, P.; Rosen, N. Akt Forms an Intracellular Complex with Heat Shock Protein 90(Hsp90) and Cdc37 and is Destabilized by Inhibitors of Hsp90 Function. J. Biol. Chem. 2002, 277, 39858-39866.